Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03379-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Neda Kortam und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, University of Michigan, 1150 W Medical Center Drive, Ann Arbor, MI, 48109, USA. Hauptthemen laut MEDLINE: Extracellular Traps, Scleroderma, Systemic, Epoprostenol. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Arthritis National Research Foundation, National Scleroderma Foundation.
Abstract (Originalsprache)
Objectives
Neutrophils and neutrophil extracellular traps (NETs) contribute to the vascular complications of multiple diseases, but their role in systemic sclerosis (SSc) is understudied. We sought to test the hypothesis that NETs are implicated in SSc vasculopathy and that treatment with prostacyclin analogs may ameliorate SSc vasculopathy not only through vasodilation but also by inhibiting NET release.
Methods
Blood from 125 patients with SSc (87 diffuse cutaneous SSc and 38 limited cutaneous SSc) was collected at a single academic medical center. Vascular complications such as digital ulcers, pulmonary artery hypertension, and scleroderma renal crisis were recorded. The association between circulating NETs and vascular complications was determined using in vitro and ex vivo assays. The impact of the synthetic prostacyclin analog epoprostenol on NET release was determined.
Results
Neutrophil activation and NET release were elevated in patients with SSc-associated vascular complications compared to matched patients without vascular complications. Neutrophil activation and NETs positively correlated with soluble E-selectin and VCAM-1, circulating markers of vascular injury. Treatment of patients with digital ischemia with a synthetic prostacyclin analog boosted neutrophil cyclic AMP, which was associated with the blunting of NET release and reduced NETs in circulation.
Conclusion
Our study demonstrates an association between NETs and vascular complications in SSc. We also identified the potential for an additional therapeutic benefit of synthetic prostacyclin analogs, namely to reduce neutrophil hyperactivity and NET release in SSc patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, University of Michigan, 1150 W Medical Center Drive, Ann Arbor, MI, 48109, USA.
- Division of Rheumatology, Department of Internal Medicine, University of Michigan, 1150 W Medical Center Drive, Ann Arbor, MI, 48109, USA. ramali@umich.edu.
Förderung
- Arthritis National Research Foundation
- National Scleroderma Foundation
Zitieren
APA
Kortam, N., Liang, W., Shiple, C., Huang, S., Gedert, R., Clair, J. S., Sarosh, C., Foster, C., Tsou, P. S., Varga, J., Knight, J. S., Khanna, D., & Ali, R. A. (2024). Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03379-6
Vancouver
Kortam N, Liang W, Shiple C, Huang S, Gedert R, Clair JS, et al. Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03379-6
BibTeX
@article{Kortam2024,
author = {Kortam, Neda and Liang, Wenying and Shiple, Claire and Huang, Suiyuan and Gedert, Rosemary and Clair, James St and Sarosh, Cyrus and Foster, Caroline and Tsou, Pei-Suen and Varga, John and Knight, Jason S and Khanna, Dinesh and Ali, Ramadan A},
title = {Elevated neutrophil extracellular traps in systemic sclerosis-associated vasculopathy and suppression by a synthetic prostacyclin analog},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03379-6}
}
EUVIMED